Optimization of Novel Acyl Pyrrolidine Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase Leading to a Development Candidate.
Slater, M.J., Amphlett, E.M., Andrews, D.M., Bravi, G., Burton, G., Cheasty, A.G., Corfield, J.A., Ellis, M.R., Fenwick, R.H., Fernandes, S., Guidetti, R., Haigh, D., Hartley, C.D., Howes, P.D., Jackson, D.L., Jarvest, R.L., Lovegrove, V.L., Medhurst, K.J., Parry, N.R., Price, H., Shah, P., Singh, O.M., Stocker, R., Thommes, P., Wilkinson, C., Wonacott, A.(2007) J Med Chem 50: 897
- PubMed: 17269759 
- DOI: https://doi.org/10.1021/jm061207r
- Primary Citation of Related Structures:  
2JC0, 2JC1 - PubMed Abstract: 
Optimization of a pyrrolidine-based template using structure-based design and physicochemical considerations has provided a development candidate 20b (3082) with submicromolar potency in the HCV replicon and good pharmacokinetic properties.
Organizational Affiliation: 
Infectious Diseases CEDD and Medicinal Discovery Research, GlaxoSmithKline, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom. martin.j.slater@gsk.com